MedTrace Logo

Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

NCT06021678 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 415

Last updated 2025-02-27

No results posted yet for this study

Summary

This is a multicenter, single-arm, open, dose-escalation Phase I/II clinical trial, consisting of a dose-escalation phase (accelerated titration phase, 3+3 design) and a dose expansion phase.

Conditions

  • CD20-positive Non-Hodgkin Lymphoma

Interventions

DRUG

EX103 injection

Administered as specified in the treatment arm.

Sponsors & Collaborators

  • Guangzhou Excelmab Inc.

    lead INDUSTRY

Principal Investigators

  • Junyuan Qi, MD, PHD · Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-12
Primary Completion
2025-10-31
Completion
2025-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06021678 on ClinicalTrials.gov